Essex Woodlands Healthcare Partners
Essex Woodlands is a healthcare growth equity and venture capital firm.
Business Model:
Revenue: $10M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Essex Woodlands Healthcare Partners Information
Geographic Data
Address: 21 Waterway Avenue
City: The Woodlands
State: TX
Zip: 77380
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$745M
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world&s;s largest and most established healthcare venture capital firms. The team is comprised of 23 professionals with principal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience. For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.
Contact Phone:
+12813641555
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2000 | WholePeople.com | Venture Round | 35M |
| 9/2015 | Kona Medical | Debt Financing | 10M |
| 12/2012 | Kona Medical | Series C | 10M |
| 7/2015 | Qspex Technologies | Debt Financing | 0 |
| 8/2000 | Control Delivery Systems | Venture Round | 0 |
| 6/2004 | Xanodyne | Venture Round | 20M |
| 12/2009 | Revance Therapeutics | Series D | 0 |
| 4/2004 | Revance Therapeutics | Series B | 13M |
| 4/2013 | Revance Therapeutics | Series E | 33M |
| 1/2006 | Touchstone Health | Private Equity Round | - |
| 2/2009 | Symphogen | Venture Round | 42.3M |
| 9/2007 | Corium International | Series C | 40M |
| 5/2007 | StrataGent Life Sciences | Series B | 0 |
| 4/2006 | Chroma Therapeutics | Series C | 53M |
| 5/2012 | NeoVista | Venture Round | 6M |
| 9/2010 | Accumetrics | Venture Round | 0 |
| 10/2009 | Accumetrics | Series E | 0 |
| 1/2003 | Iomai Corporation | Series C | 54M |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 8/2011 | Entellus Medical | Series E | 0 |
| 6/2002 | Confluent Surgical | Series C | 20M |
| 3/2005 | Confluent Surgical | Series D | 0 |
| 3/2008 | Nellix | Series C | 0 |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 1/2005 | Bausch Health | Venture Round | - |
| 6/2016 | Suneva Medical | Series D | 25M |
| 6/2009 | Chroma Therapeutics | Series D | 0 |
| 1/2002 | Symphogen | Series B | 0 |
| 8/2010 | Complete Genomics | Series E | 39M |
| 1/2005 | Dow Pharmaceutical Sciences | Venture Round | - |
| 1/2007 | Healthcare Brands International Ltd | Venture Round | - |
| 7/2020 | Cardiva Medical | Venture Round | 0 |
| 11/2004 | Symphogen | Series C | 0 |
| 7/2004 | LipoSonix | Series C | 27M |
| 12/2011 | IntegenX | Series C | 40M |
| 2/2002 | Inhibitex | Venture Round | 20M |
| 8/2001 | Spinal Concepts | Series E | 21M |
| 10/2002 | MicroMed Technology | Series D | 23M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 1/2001 | Rinat Neuroscience | Series A | 17.5M |
| 6/2007 | Millennium Pharmacy Systems | Venture Round | 40M |
| 1/2011 | Symphogen | Venture Round | 0 |
| 5/2010 | TearScience | Series C | 44.5M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 8/2009 | Complete Genomics | Series D | 45M |
| 1/2013 | Yantai Beacon Medical | Private Equity Round | - |
| 2/2017 | Xenex | Venture Round | 0 |
| 7/2009 | Oraya Therapeutics | Series C | 42M |
| 8/2016 | Metabolon | Venture Round | 0 |
| 6/2011 | Revance Therapeutics | Series D | 45M |
| 5/2012 | Kona Medical | Series C | 0 |
| 7/2007 | Horizon Pharma | Series C | 30M |
| 2/2008 | Accumetrics | Series D | 0 |
| 10/2010 | Endologix | Post-IPO Equity | 15M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 11/2009 | Entellus Medical | Series D | 30M |
| 6/2001 | InSound Medical | Venture Round | 7M |
| 1/2007 | Global Cord Blood Corporation | Private Equity Round | - |
| 9/2006 | Prism Pharmaceuticals | Series B | 15M |
| 7/2007 | Orthovita | Post-IPO Equity | 32.5M |
| 8/2015 | AxoGen | Post-IPO Equity | 0 |
| 4/2016 | TearScience | Series D | 0 |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 6/2012 | Qspex Technologies | Series D | 0 |
| 1/2010 | Velcera | Venture Round | - |
| 12/2016 | Prolacta Bioscience | Venture Round | 0 |
| 2/2007 | Alaunos Therapeutics | Post-IPO Equity | 0 |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 1/2007 | Ception Therapeutics | Series C | 63M |
| 4/2005 | Receptor Biologix | Series A | 33.6M |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 3/2009 | NeoVista | Series D | 18M |
| 2/2011 | NeoVista | Series E | 33M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 7/2004 | Accumetrics | Series B | 0 |
| 5/2012 | Bioventus | Venture Round | 0 |
| 1/2010 | ikaSystems | Private Equity Round | 120M |
| 11/2012 | BreatheAmerica | Venture Round | 5M |
| 9/2011 | BreatheAmerica | Series B | 22M |
| 1/2003 | LifeCell | Private Equity Round | - |
| 3/2007 | EUSA Pharma | Venture Round | - |
| 12/2007 | Revance Therapeutics | Series C | 0 |
| 1/2004 | BioForm Medical | Venture Round | - |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 12/2006 | NeoVista | Series C | 41M |
| 1/2001 | Cord Blood Registry | Venture Round | - |
| 10/2009 | Qspex Technologies | Venture Round | 12M |
| 6/2019 | Tissuetech | Series C | 82.3M |
| 1/2006 | Symphogen | Series D | 0 |
| 1/2008 | Oraya Therapeutics | Series B | 18M |
| 6/2007 | Oraya Therapeutics | Series A | 4M |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 7/2007 | Xanodyne | Series A | 25M |
| 1/2008 | ATS Medical | Funding Round | - |
| 1/2007 | MicroPort Scientific | Private Equity Round | - |
| 10/2010 | ProteinSimple | Series F | 20M |
| 3/2009 | Victory Pharma | Venture Round | 10M |
| 12/2011 | Grupo Biotoscana SL | Private Equity Round | - |
| 3/2000 | Healthgrades | Post-IPO Equity | 18M |
| 7/2020 | Cardiva Medical | Venture Round | 0 |
| 6/2019 | Tissuetech | Series C | 0 |
| 2/2017 | Xenex | Venture Round | 0 |
| 12/2016 | Prolacta Bioscience | Venture Round | 0 |
| 8/2016 | Metabolon | Venture Round | 0 |
| 6/2016 | Suneva Medical | Series D | 0 |
| 4/2016 | TearScience | Series D | 0 |
| 9/2015 | Kona Medical | Debt Financing | 0 |
| 8/2015 | AxoGen | Post-IPO Equity | 0 |
| 7/2015 | Qspex Technologies | Debt Financing | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
